Updated results from the international BREAKWATER phase III trial show that patients with BRAF V600E-mutated metastatic colorectal cancer may live significantly longer when treated with a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy, compared to the current standard of care for this subset of patients, which involves chemotherapy with or ...
A randomized phase 3 trial (CHALLENGE, CO.21) conducted by the Canadian Cancer Trials Group found that a 3-year structured exercise program following surgery and chemotherapy significantly improved outcomes for patients with stage III and high-risk stage II colorectal cancer. Compared to patients who only received health education materials, those in ...
New results from the Phase 3 BREAKWATER clinical trial show that a combination treatment including BRAFTOVI® (encorafenib), cetuximab, and chemotherapy significantly improves survival for patients with metastatic colorectal cancer that has a specific genetic change called the BRAF V600E mutation. In the trial, patients receiving this new treatment lived twice ...
A large phase 3 trial (ASCOLT) found that daily aspirin use for 3 years after standard adjuvant therapy (treatment given to patients following surgery) did not improve disease-free survival in an unselected population of colorectal cancer patients. Conducted across 11 countries with 1,550 participants, the study showed no statistically significant ...
A recent study published in Nature by Díaz-Gay et al. has linked early-life exposure to a bacterial toxin called colibactin, produced by certain strains of E. coli, with the rise in early-age onset colorectal cancer (EAOCRC). Researchers found colibactin-related DNA mutations were 3.3 times more common in individuals diagnosed with ...
Colorectal cancer often starts as a small polyp that slowly grows until it becomes cancerous. Research indicates that once a polyp reaches around 20mm in size, it can rapidly progress to cancer. Removing these larger polyps early is essential for preventing cancer and avoiding major treatments like surgery or chemotherapy. ...
Colorectal cancer often begins as a small polyp in the colon that slowly grows until it becomes cancerous. Research shows that once a polyp reaches about 20mm in size, it can quickly progress to cancer. Removing these larger polyps early is key to preventing cancer and avoiding major treatments like ...
March 2025 A phase 3 trial presented at the 2025 Gastrointestinal Cancers Symposium showed that three years of aspirin use significantly reduced the risk of recurrence in colorectal cancer patients with PIK3CA mutations. What is PIK3CA? PIK3CA is a gene that is commonly mutated (changed) in many types of cancer ...
March 2025 A recent study suggests that long-term yogurt intake may have a protective effect against colorectal cancer by promoting beneficial changes to the gut microbiome. Researchers focused on Bifidobacterium, a type of beneficial bacteria commonly found in yogurt, and analyzed data from over 132,000 men and women enrolled in ...
The 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held from January 23 to 25 in San Francisco, showcased several significant advancements in colorectal cancer research and treatment. Checkmate-8HW Trial: Nivolumab + Ipilimumab Demonstrates Improved Outcomes Over Standard Therapies For MSI-H/dMMR Metastatic Colorectal Cancer What is CheckMate-8HW? ...
1 Westmount Square, Suite 1630
Westmount, QC H3Z 2P9
Canada
info@colorectalcancercanada.com
© Colorectal Cancer Canada All rights reserved
Charitable registration number 86657 2423 RR0001
